Cellectis shares slump as death puts cell therapy tests on hold [Reuters (UK)]
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: Reuters
Cellectis shares slump as death puts cell therapy tests on hold | Reuters 3 Min Read LONDON (Reuters) - French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis’s recently approved Kymriah, has been forced to suspend testing following a patient death. Cellectis said on Tuesday it was working closely with the U.S. Food and Drug Administration in order to resume trials with a lower dose of the medicine UCART123. Shares in the company fell 26 percent in morning trade following the U.S. regulator’s decision to place a so-called clinical hold on two early-stage trials of the medicine in blood cancers. Novartis made history last week when it won approval for its $475,000 drug Kymriah, the first in a new class of treatments called CAR-T immunotherapies that use modified disease-fighting T cells to attack cancer. While Novartis and rivals such as Juno and Kite use cells from the patient’s own body, Cellectis’s gene edited cell therapy
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- AstraZeneca concludes equity investment in Cellectis [Yahoo! Finance]Yahoo! Finance
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca [Yahoo! Finance]Yahoo! Finance
- Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaGlobeNewswire
- Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Cellectis Appoints Arthur Stril as Interim Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
CLLS
Earnings
- 11/6/23 - In-Line
CLLS
Sec Filings
- 5/6/24 - Form 6-K
- 5/3/24 - Form 6-K
- 4/29/24 - Form 20-F
- CLLS's page on the SEC website